Irinotecan liposomal - CSPC Ouyi Pharmaceutical
Alternative Names: Irinotecan liposome injection - CSPC Ouyi PharmaceuticalLatest Information Update: 13 Feb 2026
At a glance
- Originator CSPC Ouyi Pharmaceutical
- Developer CSPC Ouyi Pharmaceutical; CSPC Pharmaceutical Group
- Class Alcohols; Alkaloids; Alkanes; Antineoplastics; Camptothecins; Esters; Indolizines; Ketones; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Small cell lung cancer; Squamous cell cancer
- Phase I/II Malignant ascites
- No development reported Breast cancer; Pancreatic cancer
Most Recent Events
- 28 Nov 2025 Phase-I/II clinical trials in Malignant ascites (Combination therapy, Second-line therapy or greater) in China (Intraperitoneal) (NCT07397819)
- 28 Nov 2025 Phase-I/II clinical trials in Malignant ascites (Monotherapy, Second-line therapy or greater) in China (Intraperitoneal) (NCT07397819)
- 17 Oct 2025 Efficacy and adverse events data from a phase II trial in Squamous cell cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)